Vmbook Online ordering

Access Pharmaceuticals Inc

I assume you are asking about a public company in the pharmaceutical sector with the ticker "ACP" on a US stock exchange. After some research, I found that the ticker "ACP" belongs to Acorda Therapeutics, Inc., a biotech company based in the US that focuses on developing therapies for neurological disorders.

Here are some general details about Acorda Therapeutics:

* **Business Description:** Acorda Therapeutics is a biopharmaceutical company dedicated to developing and commercializing therapies that improve the lives of people with neurological disorders.

* **Recent Earnings:** For Q3 2022, Acorda Therapeutics reported a net loss of $48.3 million, or $0.65 per share, compared to a net loss of $35.4 million, or $0.50 per share, in Q3 2021. The company's revenue for Q3 2022 was $22.5 million, compared to $23.3 million in Q3 2021.

* **Growth:** Acorda Therapeutics has faced some challenges in recent years, including the loss of exclusivity for its lead drug, AMPYRA, in 2018. However, the company has been working to expand its pipeline and diversify its portfolio, including through partnerships and collaborations with other companies.

* **Valuation:** As of February 2, 2023, Acorda Therapeutics has a market capitalization of approximately $123 million and a price-to-earnings (P/E) ratio of around -25.6, based on its trailing 12-month earnings.

It is important to note that the information presented here is based on publicly available data as of a certain date and may have changed since then. Additionally, the information presented here should not be taken as a recommendation or investment advice. Investors should do their own research and consult with their financial advisors before making any investment decisions.